ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - PI3K Inhibitors

ODACon™ Supportive Care Summit: Managing Toxicities of Novel Breast Cancer Therapies - PI3K Inhibitors is organized by i3 Health and will be held from Dec 07, 2022 - Dec 06, 2023.,Statement of Need:,Breast cancer is the most diagnosed cancer in women, with hormone receptor (HR)–positive/human epidermal growth factor receptor 2 (HER2)–negative breast cancer being the most common subtype, making up 73% of cases (ACS, 2019). In breast cancer, phosphatidylinositol-3-kinase (PI3K) overactivation is often associated with an activating mutation in the catalytic alpha subunit of PI3K (PIK3CA). These activating mutations occur in more than one third of breast cancers (Verret et al, 2019). The PI3K/Akt signaling pathway is strongly associated with cell proliferation, migration, and survival and is commonly activated in cancer. Alpelisib was the first PI3K inhibitor approved for breast cancer in 2019, in combination with fulvestrant for patients with metastatic HR-positive/HER2-negative breast cancer and a PIK3CA activation mutation (Andre et al, 2019). In this session, Janie Metsker, RN, BSN, CN-BN will explore the role of PI3K inhibitors for patients with breast cancer, including the advantages of isoform-specific inhibition of PI3K with alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents. ,Learning Objectives:,Upon completion of this activity, participants should be able to,In this session, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at the Koontz Center for Advanced Breast Cancer at Saint Luke’s Hospital, Kansas City, Missouri, will explore the role of PI3K inhibitors for patients with a mutation in PIK3CA nd HR-positive, HER2-negative breast cancer, including alpelisib. She will explain how PI3K inhibition is thought to help overcome resistance to hormonal therapy for breast cancer and will review the safety concerns associated with PI3K agents.